Literature DB >> 24475817

Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.

Hebert Alberto Vargas1, Cecilia Wassberg, Josef J Fox, Andreas Wibmer, Debra A Goldman, Deborah Kuk, Mithat Gonen, Steven M Larson, Michael J Morris, Howard I Scher, Hedvig Hricak.   

Abstract

PURPOSE: To compare the features of bone metastases at computed tomography (CT) to tracer uptake at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and fluorine 18 16β-fluoro-5-dihydrotestosterone (FDHT) PET and to determine associations between these imaging features and overall survival in men with castration-resistant prostate cancer.
MATERIALS AND METHODS: This is a retrospective study of 38 patients with castration-resistant prostate cancer. Two readers independently evaluated CT, FDG PET, and FDHT PET features of bone metastases. Associations between imaging findings and overall survival were determined by using univariate Cox proportional hazards regression.
RESULTS: In 38 patients, reader 1 detected 881 lesions and reader 2 detected 867 lesions. Attenuation coefficients at CT correlated inversely with FDG (reader 1: r = -0.3007; P < .001; reader 2: r = -0.3147; P < .001) and FDHT (reader 1: r = -0.2680; P = .001; reader 2: r = -0.3656; P < .001) uptake. The number of lesions on CT scans was significantly associated with overall survival (reader 1: hazard ratio [HR], 1.025; P = .05; reader 2: HR, 1.021; P = .04). The numbers of lesions on FDG and FDHT PET scans were significantly associated with overall survival for reader 1 (HR, 1.051-1.109; P < .001) and reader 2 (HR, 1.026-1.082; P ≤ .009). Patients with higher FDHT uptake (lesion with the highest maximum standardized uptake value) had significantly shorter overall survival (reader 1: HR, 1.078; P = .02; reader 2: HR, 1.092; P = .02). FDG uptake intensity was not associated with overall survival (reader 1, P = .65; reader 2, P = .38).
CONCLUSION: In patients with castration-resistant prostate cancer, numbers of bone lesions on CT, FDG PET, and FDHT PET scans and the intensity of FDHT uptake are significantly associated with overall survival. RSNA, 2013

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24475817      PMCID: PMC4263648          DOI: 10.1148/radiol.13130625

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  25 in total

1.  Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates.

Authors:  F Y Hsieh; P W Lavori
Journal:  Control Clin Trials       Date:  2000-12

Review 2.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

3.  Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjects.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1995-02-18

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

Review 5.  Bone metastases: pathophysiology and management policy.

Authors:  O S Nielsen; A J Munro; I F Tannock
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

6.  Detection of bony metastases of androgen-independent prostate cancer by PET-FDG.

Authors:  S D Yeh; M Imbriaco; S M Larson; D Garza; J J Zhang; H Kalaigian; R D Finn; D Reddy; S M Horowitz; S J Goldsmith; H I Scher
Journal:  Nucl Med Biol       Date:  1996-08       Impact factor: 2.408

Review 7.  Imaging of castration-resistant prostrate cancer: development of imaging response biomarkers.

Authors:  Courtney Morisson; Robert Jeraj; Glenn Liu
Journal:  Curr Opin Urol       Date:  2013-05       Impact factor: 2.309

Review 8.  The Warburg effect: insights from the past decade.

Authors:  Mohita Upadhyay; Jasmine Samal; Manish Kandpal; Om Vir Singh; Perumal Vivekanandan
Journal:  Pharmacol Ther       Date:  2012-11-16       Impact factor: 12.310

9.  Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.

Authors:  Steven M Larson; Michael Morris; Ilonka Gunther; Brad Beattie; John L Humm; Timothy A Akhurst; Ronald D Finn; Yusuf Erdi; Keith Pentlow; Jon Dyke; Olivia Squire; William Bornmann; Timothy McCarthy; Michael Welch; Howard Scher
Journal:  J Nucl Med       Date:  2004-03       Impact factor: 10.057

10.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.

Authors:  P D Shreve; H B Grossman; M D Gross; R L Wahl
Journal:  Radiology       Date:  1996-06       Impact factor: 11.105

View more
  36 in total

Review 1.  Radiopharmaceuticals as probes to characterize tumour tissue.

Authors:  Israt S Alam; Mubarik A Arshad; Quang-Dé Nguyen; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

2.  Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.

Authors:  Hebert Alberto Vargas; Gem M Kramer; Andrew M Scott; Andrew Weickhardt; Andreas A Meier; Nicole Parada; Bradley J Beattie; John L Humm; Kevin D Staton; Pat B Zanzonico; Serge K Lyashchenko; Jason S Lewis; Maqsood Yaqub; Ramon E Sosa; Alfons J van den Eertwegh; Ian D Davis; Uwe Ackermann; Kunthi Pathmaraj; Robert C Schuit; Albert D Windhorst; Sue Chua; Wolfgang A Weber; Steven M Larson; Howard I Scher; Adriaan A Lammertsma; Otto S Hoekstra; Michael J Morris
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

3.  Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer.

Authors:  Mark Lazari; Serge K Lyashchenko; Eva M Burnazi; Jason S Lewis; R Michael van Dam; Jennifer M Murphy
Journal:  Appl Radiat Isot       Date:  2015-05-21       Impact factor: 1.513

Review 4.  Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.

Authors:  Daniel P Petrylak; E David Crawford
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 5.  Is There Use for FDG-PET in Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

Review 6.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

Review 7.  PET imaging of recurrent and metastatic prostate cancer with novel tracers.

Authors:  Francesca V Mertan; Liza Lindenberg; Peter L Choyke; Baris Turkbey
Journal:  Future Oncol       Date:  2016-08-16       Impact factor: 3.404

Review 8.  PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

Review 9.  [Focus on molecular imaging in prostate cancer].

Authors:  L Michaud; K A Touijer
Journal:  Prog Urol       Date:  2016-09-20       Impact factor: 0.915

Review 10.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.